The effect of food on the pharmacokinetic properties and bioequivalence of two formulations of pitavastatin calcium in healthy Chinese male subjects

References

• Ando H, Tsuruoka S, Yanagihara H, et al. (2005). Effects of grapefruit juice on the pharmacokinetics of pitavastatin and atorvastatin. Br J Clin Pharmacol 60:494–7
   PubMed Web of Science ®Google Scholar
• Aoki T, Nishimura H, Nakagawa S, et al. (1997). Pharmacological profile of a novel synthetic inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Arzneimittelforschung 47:904–9
   PubMed Web of Science ®Google Scholar
• Catapano LA. (2012). Statin-induced myotoxicity: pharmacokinetic differences among statins and the risk of rhabdomyolysis, with particular reference to pitavastatin. Curr Vasc Pharmacol 10:257–67
   PubMed Web of Science ®Google Scholar
• Charman WN, Porter CJ, Mithani S, et al. (1997). Physiochemical and physiological mechanisms for the effects of food on drug absorption: the role of lipids and pH. J Pharm Sci 86:269–82
   PubMed Web of Science ®Google Scholar
• Chen Y, Zhang W, Huang WH, et al. (2013). Effect of a single-dose rifampin on the pharmacokinetics of pitavastatin in healthy volunteers. Eur J Clin Pharmacol 69:1933–8
   PubMed Web of Science ®Google Scholar
• ChP, (Edition 2010). Guideline on the investigation of bioavailability and bioequivalence study of drug products. Appendix XIX B. 195
   Google Scholar
• Chung JY, Cho JY, Yu KS, et al. (2005). Effect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers & ast. Clin Pharmacol Ther 78:342–50
   PubMed Web of Science ®Google Scholar
• Fujino H, Yamada I, Kojima J, et al. (1999). Studies on the metabolic fate of NK-104, a new inhibitor of HMGCoA reductase: in vitro metabolism and plasma protein binding in animals and human. Drug Metab Pharmacokinet 14:415–24
   Google Scholar
• Fujino H, Yamada I, Shimada S, et al. (2003). Metabolic fate of pitavastatin, a new inhibitor of HMG-CoA reductase: human UDP-glucuronosyl transferase enzymes involved in lactonization. Xenobiotica 33:27–41
   PubMed Web of Science ®Google Scholar
• Hirano M, Maeda K, Shitara Y, et al. (2004). Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J Pharmacol Exp Ther 311:139–46
   PubMed Web of Science ®Google Scholar
• Hu M, Mak VW, Yin OQ, et al. (2012). Effects of grapefruit juice and SLCO1B1 388A >G polymorphism on the pharmacokinetics of pitavastatin. Drug Metab Pharmacokinet 28:104–8
   PubMed Web of Science ®Google Scholar
• Huang YH, Li ZQ, Pan GX, et al. (2014). Comparison of scaled-average, population, and individual bioequivalence on 2 tablets of pitavastatin calcium: a 3-period, reference-replicated, crossover study in healthy Chinese volunteers. Clin Ther 36:1205–16
   PubMed Web of Science ®Google Scholar
• Ieiri I, Higuchi S, Sugiyama Y. (2009). Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs. Expert Opin Drug Metab Toxicol 5:703–29
   PubMed Web of Science ®Google Scholar
• Inagaki Y, Hunt T, Arana B, et al. (2011). Drug-drug interaction study to assess the effects of multiple-dose pitavastatin on steady-state warfarin in healthy adult volunteers. J Clin Pharmacol 51:1302–9
   PubMed Web of Science ®Google Scholar
• Lv H, Sun JG, Wang GJ, et al. (2007). Determination of pitavastatin in human plasma via HPLC-ESI-MS/MS and subsequent application to a clinical study in healthy Chinese volunteers. Clin Chim Acta 386:25–30
   PubMed Web of Science ®Google Scholar
• Maejima T, Yamazaki H, Aoki T, et al. (2004). Effect of pitavastatin on apolipoprotein A-I production in HepG2 cell. Biochem Biophys Res Commun 324:835–9
   PubMed Web of Science ®Google Scholar
• Malvestutto CD, Ma Q, Morse GD, et al. (2014). Lack of pharmacokinetic interactions between pitavastatin and efavirenz or darunavir/ritonavir. J Acquir Immune Defic Syndr 67:390–6
   PubMed Web of Science ®Google Scholar
• Mukhtar RYA, Reid J, Reckless JPD. (2005). “Pitavastatin”. Int J Clin Pract 59:239–52
   PubMed Web of Science ®Google Scholar
• Ose L, Budinski D, Hounslow N, et al. (2009). Comparison of pitavastatin with simvastatin in primary hypercholesterolaemia or combined dyslipidaemia. Curr Med Res Opin 25:2755–64
   PubMed Web of Science ®Google Scholar
• Pasanen MK, Neuvonen PJ, Niemi M. (2008). Global analysis of genetic variation in SLCO1B1. Pharmacogenomics 9:19–33
   PubMed Web of Science ®Google Scholar
• Qi X, Ding L, Wen A, et al. (2013). Simple LC-MS/MS methods for simultaneous determination of pitavastatin and its lactone metabolite in human plasma and urine involving a procedure for inhibiting the conversion of pitavastatin lactone to pitavastatin in plasma and its application to a pharmacokinetic study. J Pharm Biomed Anal 72:8–15
   PubMed Web of Science ®Google Scholar
• Requena-Méndez A, Davies G, Waterhouse D, et al. (2014). Effects of dosage, comorbidities, and food on isoniazid pharmacokinetics in Peruvian tuberculosis patients. Antimicrob Agents Chemother 58:7164–70
   PubMed Web of Science ®Google Scholar
• Saiki A, Murano T, Watanabe F, et al. (2005). Pitavastatin enhanced lipoprotein lipase expression in 3T3-L1 preadipocytes. J Atheroscler Thromb 12:163–8
   PubMed Web of Science ®Google Scholar
• Saito Y, Yamada N, Teramoto T, et al. (2002). A randomized, double-blind trial comparing the efficacy and safety of pitavastatin versus pravastatin in patients with primary hypercholesterolemia. Atherosclerosis 162:373–9
   PubMed Web of Science ®Google Scholar
• Sasaki J, Ikeda Y, Kuribayashi T, et al. (2008). A 52-week, randomized, open-label, parallel group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of lowdensity lipoprotein cholesterol and glucose intolerance. Clin Ther 30:1089–101
   PubMed Web of Science ®Google Scholar
• Schachter M. (2005). Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fund Clin Pharmacol 19:117–25
   PubMed Web of Science ®Google Scholar
• Tirona RG. (2005). Ethnic differences in statin disposition. Clin Pharmacol Ther 78:330–41
   PubMed Web of Science ®Google Scholar
• Wen J, Xiong Y. (2010). OATP1B1 388A > G polymorphism and pharmacokinetics of pitavastatin in Chinese healthy volunteers. J Clin Pharm Ther 35:99–104
   PubMed Web of Science ®Google Scholar
• World Medical Association. (2013). Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 310:2191--4
   Google Scholar
• Xu LY, He YJ, Zhang W. (2007). Organic anion transporting polypeptide-1B1 haplotypes in Chinese patients. Acta Pharmacol Sin 28:1693–7
   PubMed Web of Science ®Google Scholar
• Yee LL, Wright EA. (2011). Pitavastatin calcium: clinical review of a new antihyperlipidemic medication. Clin Ther 33:1023–42
   PubMed Web of Science ®Google Scholar